Glancy Prongay Wolke & Rotter LLP reminds investors that June 23, 2026 is the deadline to file a lead plaintiff motion in a class action lawsuit against Regencell Bioscience Holdings Limited. The suit covers investors who purchased or acquired Regencell securities between October 28, 2024 and October 31, 2025. The complaint alleges the company made false or misleading statements and failed to disclose risks including vulnerability to market manipulation and heightened regulatory scrutiny. On October 31, 2025, Regencell disclosed a Department of Justice investigation into trading in its ordinary shares, causing its stock price to fall $3.09, or 18.56%, to close at $13.56 per share on November 3, 2025.
Regencell Bioscience Holdings LtdCompany faces securities fraud lawsuit and DOJ investigation, with alleged false statements and regulatory scrutiny.